{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026227","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.472907+00:00","generated_at":"2026-06-21T07:15:01.056937+00:00","sec_items":["1.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cytokinetics amends Royalty Pharma loan, extends draw deadlines to Mar 31, 2023","bullets":["Amendment extends deadline for Tranche 2 and Tranche 3 Term Loans from Dec 31, 2022 to Mar 31, 2023.","Repayment amount for those tranches increased from 190% to 200% of principal as consideration.","Original Loan Agreement provided up to $300M for omecamtiv mecarbil, aficamten, and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026227","json":"https://secwatch.observer/filing/0000950170-22-026227.json","markdown":"https://secwatch.observer/filing/0000950170-22-026227.md","text":"https://secwatch.observer/filing/0000950170-22-026227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017022026227/0000950170-22-026227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017022026227/cytk-20221208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:15:01.056937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bed0acbfc43ac8446562a4a60386e207c3b0edef","claim":"CYTOKINETICS INC amended Second Amendment to Development Funding Loan Agreement with Royalty Pharma Development Funding, LLC (effective 2022-12-08).","evidence_excerpt":"The Amendment extends the deadline dates, from December 31, 2022, to March 31, 2023, for which each of the respective conditions of the Tranche 2 Term Loans and Tranche 3 Term Loans must occur in order for Cytokinetics to be able to draw on these loans.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017022026227/0000950170-22-026227-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Royalty Pharma Development Funding, LLC"},{"label":"Effective","value":"2022-12-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}